Management of hyperprolactinemic infertility

P. G. Crosignani

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pathological hyperprolactinemia may cause defective ovulation and reduced fecundability. Abnormal prolactin (PRL) secretion is usually related to an idiopathic hypothalamic dysfunction or to the presence of a pituitary adenoma. The use of medication is the most common cause of functional hyperprolactinemia. Pituitary prolactin secreting adenoma is classified according to size: micro (the vast majority) being smaller than 10 mm in diameter or macroprolactinoma (very few) of larger size. An excessive PRL secretion decreases the pulsatile release of GnRH impairing the pituitary production of FSH and LH. Furthermore it may directly impair the endocrine activity of ovarian follicles. As a consequence: defective luteal phase, inconstant ovulation and chronic anovulation are conditions frequently observed in young hyperprolactinemic patients. In addition 5% of unselected, asymptomatic infertile women show hyperprolactinemia. In such patients fertility may be promoted with long-term use of dopaminergic drugs. The normalized PRL level induced by the treatment allows the occurrence of spontaneous ovulatory cycles or the normalization of the defective luteal phase. Treatment should be continued for at least one year since half of the pregnancies occurring during dopaminergic therapy start after the first 6 months of drug assumption. An ovarian stimulation with gonadotropin and the pulsatile administration of GnRH may also induce ovulatory cycles and fertility in the infertile hyperprolactinemic patients. Hyperprolactinemia either, due to hypothalamic dysfunction, as well as the presence of PRL secreting adenoma usually improves after delivery.

Original languageEnglish
Pages (from-to)63-69
Number of pages7
JournalMiddle East Fertility Society Journal
Volume17
Issue number2
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Hyperprolactinemia
Prolactin
Infertility
Fertility
Prolactinoma
Luteal Phase
Ovulation
Gonadotropin-Releasing Hormone
Anovulation
Dopamine Agents
Ovarian Follicle
Ovulation Induction
Pituitary Neoplasms
Gonadotropins
Adenoma
Therapeutics
Pregnancy
Pharmaceutical Preparations

Keywords

  • Anovulation
  • Defective luteal phase
  • Hyperprolactinemia
  • Pituitary adenoma
  • Prolactinoma

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Management of hyperprolactinemic infertility. / Crosignani, P. G.

In: Middle East Fertility Society Journal, Vol. 17, No. 2, 06.2012, p. 63-69.

Research output: Contribution to journalArticle

Crosignani, P. G. / Management of hyperprolactinemic infertility. In: Middle East Fertility Society Journal. 2012 ; Vol. 17, No. 2. pp. 63-69.
@article{259963002e444310bf129d835548b1cb,
title = "Management of hyperprolactinemic infertility",
abstract = "Pathological hyperprolactinemia may cause defective ovulation and reduced fecundability. Abnormal prolactin (PRL) secretion is usually related to an idiopathic hypothalamic dysfunction or to the presence of a pituitary adenoma. The use of medication is the most common cause of functional hyperprolactinemia. Pituitary prolactin secreting adenoma is classified according to size: micro (the vast majority) being smaller than 10 mm in diameter or macroprolactinoma (very few) of larger size. An excessive PRL secretion decreases the pulsatile release of GnRH impairing the pituitary production of FSH and LH. Furthermore it may directly impair the endocrine activity of ovarian follicles. As a consequence: defective luteal phase, inconstant ovulation and chronic anovulation are conditions frequently observed in young hyperprolactinemic patients. In addition 5{\%} of unselected, asymptomatic infertile women show hyperprolactinemia. In such patients fertility may be promoted with long-term use of dopaminergic drugs. The normalized PRL level induced by the treatment allows the occurrence of spontaneous ovulatory cycles or the normalization of the defective luteal phase. Treatment should be continued for at least one year since half of the pregnancies occurring during dopaminergic therapy start after the first 6 months of drug assumption. An ovarian stimulation with gonadotropin and the pulsatile administration of GnRH may also induce ovulatory cycles and fertility in the infertile hyperprolactinemic patients. Hyperprolactinemia either, due to hypothalamic dysfunction, as well as the presence of PRL secreting adenoma usually improves after delivery.",
keywords = "Anovulation, Defective luteal phase, Hyperprolactinemia, Pituitary adenoma, Prolactinoma",
author = "Crosignani, {P. G.}",
year = "2012",
month = "6",
doi = "10.1016/j.mefs.2012.04.003",
language = "English",
volume = "17",
pages = "63--69",
journal = "Middle East Fertility Society Journal",
issn = "1110-5690",
publisher = "Middle East Fertility Society",
number = "2",

}

TY - JOUR

T1 - Management of hyperprolactinemic infertility

AU - Crosignani, P. G.

PY - 2012/6

Y1 - 2012/6

N2 - Pathological hyperprolactinemia may cause defective ovulation and reduced fecundability. Abnormal prolactin (PRL) secretion is usually related to an idiopathic hypothalamic dysfunction or to the presence of a pituitary adenoma. The use of medication is the most common cause of functional hyperprolactinemia. Pituitary prolactin secreting adenoma is classified according to size: micro (the vast majority) being smaller than 10 mm in diameter or macroprolactinoma (very few) of larger size. An excessive PRL secretion decreases the pulsatile release of GnRH impairing the pituitary production of FSH and LH. Furthermore it may directly impair the endocrine activity of ovarian follicles. As a consequence: defective luteal phase, inconstant ovulation and chronic anovulation are conditions frequently observed in young hyperprolactinemic patients. In addition 5% of unselected, asymptomatic infertile women show hyperprolactinemia. In such patients fertility may be promoted with long-term use of dopaminergic drugs. The normalized PRL level induced by the treatment allows the occurrence of spontaneous ovulatory cycles or the normalization of the defective luteal phase. Treatment should be continued for at least one year since half of the pregnancies occurring during dopaminergic therapy start after the first 6 months of drug assumption. An ovarian stimulation with gonadotropin and the pulsatile administration of GnRH may also induce ovulatory cycles and fertility in the infertile hyperprolactinemic patients. Hyperprolactinemia either, due to hypothalamic dysfunction, as well as the presence of PRL secreting adenoma usually improves after delivery.

AB - Pathological hyperprolactinemia may cause defective ovulation and reduced fecundability. Abnormal prolactin (PRL) secretion is usually related to an idiopathic hypothalamic dysfunction or to the presence of a pituitary adenoma. The use of medication is the most common cause of functional hyperprolactinemia. Pituitary prolactin secreting adenoma is classified according to size: micro (the vast majority) being smaller than 10 mm in diameter or macroprolactinoma (very few) of larger size. An excessive PRL secretion decreases the pulsatile release of GnRH impairing the pituitary production of FSH and LH. Furthermore it may directly impair the endocrine activity of ovarian follicles. As a consequence: defective luteal phase, inconstant ovulation and chronic anovulation are conditions frequently observed in young hyperprolactinemic patients. In addition 5% of unselected, asymptomatic infertile women show hyperprolactinemia. In such patients fertility may be promoted with long-term use of dopaminergic drugs. The normalized PRL level induced by the treatment allows the occurrence of spontaneous ovulatory cycles or the normalization of the defective luteal phase. Treatment should be continued for at least one year since half of the pregnancies occurring during dopaminergic therapy start after the first 6 months of drug assumption. An ovarian stimulation with gonadotropin and the pulsatile administration of GnRH may also induce ovulatory cycles and fertility in the infertile hyperprolactinemic patients. Hyperprolactinemia either, due to hypothalamic dysfunction, as well as the presence of PRL secreting adenoma usually improves after delivery.

KW - Anovulation

KW - Defective luteal phase

KW - Hyperprolactinemia

KW - Pituitary adenoma

KW - Prolactinoma

UR - http://www.scopus.com/inward/record.url?scp=84862892800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862892800&partnerID=8YFLogxK

U2 - 10.1016/j.mefs.2012.04.003

DO - 10.1016/j.mefs.2012.04.003

M3 - Article

VL - 17

SP - 63

EP - 69

JO - Middle East Fertility Society Journal

JF - Middle East Fertility Society Journal

SN - 1110-5690

IS - 2

ER -